134 related articles for article (PubMed ID: 1474934)
1. A prospective study on correlation between the decrease in anti-P17 antibody level and progression to AIDS in asymptomatic carriers of HIV.
Choudhury AM; Yamada O; Wakamiya N; Kurimura T
Microbiol Immunol; 1992; 36(8):833-40. PubMed ID: 1474934
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
[TBL] [Abstract][Full Text] [Related]
3. Disappearance of anti-p17 correlates with successful isolation of human immunodeficiency virus and deterioration in clinical status.
Kageyama S; Kurimura T
Int J STD AIDS; 1990 Mar; 1(2):129-31. PubMed ID: 2092788
[TBL] [Abstract][Full Text] [Related]
4. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.
Chargelegue D; Colvin BT; O'Toole CM
AIDS; 1993 Nov; 7 Suppl 2():S87-90. PubMed ID: 7909231
[TBL] [Abstract][Full Text] [Related]
5. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.
Chargelegue D; O'Toole CM; Colvin BT
Clin Exp Immunol; 1993 Sep; 93(3):331-6. PubMed ID: 8370162
[TBL] [Abstract][Full Text] [Related]
6. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
[TBL] [Abstract][Full Text] [Related]
7. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
9. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.
Jiang JD; Chu FN; Naylor PH; Kirkley JE; Mandeli J; Wallace JI; Sarin PS; Goldstein AL; Holland JF; Bekesi JG
J Acquir Immune Defic Syndr (1988); 1992; 5(4):382-90. PubMed ID: 1372353
[TBL] [Abstract][Full Text] [Related]
10. [Anti-HIV-1 p17 antibody as anti-HIV agent].
Tsuchie H; Tochikura A; Kageyama S; Kurimura T
Nihon Rinsho; 1993 Sep; 51 Suppl():213-8. PubMed ID: 8271386
[No Abstract] [Full Text] [Related]
11. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection.
Mehta SU; Rupprecht KR; Hunt JC; Kramer DE; McRae BJ; Allen RG; Dawson GJ; Devare SG
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):443-54. PubMed ID: 1692727
[TBL] [Abstract][Full Text] [Related]
12. Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen.
Hashida S; Ishikawa S; Nishikata I; Hashinaka K; Oka S; Ishikawa E
J Clin Lab Anal; 1998; 12(6):329-36. PubMed ID: 9850183
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
[TBL] [Abstract][Full Text] [Related]
14. Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera.
Liu X; Ota A; Watanabe M; Ueda S; Saitoh A; Shinagawa H; Nakata A; Kurimura T; Wang X; Zhao Y
Microbiol Immunol; 1995; 39(10):775-85. PubMed ID: 8577268
[TBL] [Abstract][Full Text] [Related]
15. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance.
Allain JP; Laurian Y; Einstein MH; Braun BP; Delaney SR; Stephens JE; Daluga CK; Dahlen SJ; Knigge KM
Blood; 1991 Mar; 77(5):1118-23. PubMed ID: 1671648
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
18. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
Ota A; Bautista AN; Yadav ML; Ueda S
Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
[TBL] [Abstract][Full Text] [Related]
19. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
